Medicine Overview of Rapine 15mg Tablet
Rapine 15 is a prescription medicine used in the treatment of depression. This medicine helps by increasing the level of chemical messengers (serotonin and noradrenaline) in the brain that have a calming effect on the brain and relax the nerves, thus treating your depression.
Rapine 15 may be taken with or without food. It is advised to take this medicine at a fixed time each day to maintain a consistent level in the blood. If you miss any doses, take it as soon as you remember. Do not skip any doses and finish the full course of treatment even if you feel better. It is important that this medication is not stopped suddenly as it may worsen your symptoms.
Some common side effects of this medicine include dryness in mouth, increased appetite, and headaches. It even causes dizziness and sleepiness, so do not drive or do anything that requires mental focus until you know how this medicine affects you. This medicine may cause weight gain; therefore, you should have a balanced diet and exercise regularly. Moreover, it is important to inform your doctor if you develop a sore throat or fever after taking this medicine.
Show less
- Depression
- Sleepiness
- Dryness in mouth
- Increased appetite
- Headache
- Weight gain
-
Rapine 15 starts to work more quickly than other antidepressants.
-
Avoid driving or operating dangerous machinery as it may decrease alertness.
-
Avoid consuming alcohol when taking the Rapine 15, as it may cause excessive drowsiness and calmness.
-
If your doctor asks you to stop Rapine 15, you should reduce the dose slowly over 4 weeks. You should not discontinue it abruptly.
-
Notify your doctor immediately if you develop a sore throat or fever or stomatitis during treatment with Rapine 15.
Oral
Depression
Adult: Initially, 15 mg daily; may be increased gradually depending on clinical response. Change dose at intervals of at least 1-2 wk. Usual effective dose: 15-45 mg daily given as single dose, preferably at bedtime, or in 2 divided doses.
Elderly
Depression
7.5 mg/day PO qHS; increase by 7.5-15 mg/day no more frequently than q1-2Weeks; not to exceed 45 mg/day
Alzheimer Dementia-related Depression
7.5 mg/day PO qHS; increase by 7.5-15 mg/day no more frequently than q1-2Weeks; not to exceed 60 mg/day
Hepatic impairment: Clearance is reduced; monitor closely
Show less
Renal impairment (CrCl <39 mL/min): Clearance is reduced; monitor closely
Show less
Epilepsy or history of seizures; avoid completely in unstable cases. Hepatic or renal impairment, cardiac disorders e.g. conduction disturbances, angina pectoris, recent MI. Hypotension, DM, psychoses, history of bipolar disorder. Stop treatment if jaundice develops. Micturition disturbances, angle-closure glaucoma, raised intraocular pressure. Monitor patient for signs of bone marrow depression. Monitor patient for suicidal tendency. Avoid abrupt withdrawal. May impair ability to drive or operate machinery. Pregnancy and lactation. Elderly.
Lactation: Avoid
Show less
>10%
Somnolence (54%),Weight gain (>7% increase in <49% of pediatric patients),Xerostomia (25%),Increased appetite (17%),Constipation (13%)
1-10%
Asthenia (8%),lWeakness (8%),Weight gain (>7% increase in 8% of adults),Dizziness (7%),Serum TGs increased (6%),Dream disorder (4%),Disturbance in thinking (3%),ALT increased (2%),Peripheral edema (2%),Myalgia (2%),Confusion (2%),Urinary frequency (2%),Tremor (2%),Back pain (2%),Dyspnea (1%)
<1%
Mania (0.2%),Grand mal seizure (less than 0.1%)
Frequency Not Defined
Depression exacerbation,Status epilepticus,Suicidal thoughts, suicide (rare),Agranulocytosis,Neutropenia
Show less
Potentiation of sedative effects with alcohol or benzodiazepines. Increased plasma levels with potent CYP3A4 inhibitors (e.g. HIV-protease inhibitors, azole antifungals including ketoconazole, erythromycin, nefazodone). Reduced plasma levels with carbamazepine and other inducers of CYP3A4. Increased bioavailability with cimetidine.
Potentially Fatal: Do not use with or within 2 wk of stopping an MAOI; at least 1 wk should elapse between discontinuing mirtazapine and initiating any drug which may provoke a serious reaction (e.g. phenelzine).
Show less
Reviews
Clear filtersThere are no reviews yet.